Biological replacement heart valves

Butany, Jagdish; Fayet, Cristina; Ahluwalia, Manmeet; Blit, Patrick; Ahn, Christina; Munroe, Craig A.; Israel, Noobar; Cusimano, Roberto J.; Leask, Richard L.

doi:10.1016/s1054-8807(03)00002-4

Cited by 43 publications

(16 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These are usually treated with glutraldehyde (GA), which enhances the degradation resistance of the xenograft by forming the crosslinks between complex tissue proteins. 17,20 Glutraldehyde treated xenografts have more stable mechanical properties than mechanical prosthesis, offer unlimited supply from donors and do not involve the risk of thrombosis, elimination of anticoagulation treatment and hemolysis. 8,9 However, xenografts are prone to immunogenic response and transmission of certain type of disease such as Creutzfeldt-Jakob.…”

Section: Heart Implants/prosthesismentioning

confidence: 99%

Collagen–hyaluronic acid based interpenetrating polymer networks as tissue engineered heart valve

Nazir

2016

Materials Science and Technology

View full text Add to dashboard Cite

Currently, custom made heart implants suffer from critical imperfections in terms of mechanical incompatibility and uncontrolled degradation rate, which leads to premature in vivo failure. Interpenetrating polymer networks (IPNs) are a success story in drug delivery and regenerative medicine where they offer fascinating morphologies and tailored properties like controlled degradation rate. This review will critically discuss the current state of the art with respect to the two most important biopolymers found in heart valve, i.e. collagen and hyaluronic acid formulated IPNs as tissue engineered heart valve (TEHV). Comparison of the existing experimental approaches and recent technical challenges will be demonstrated. Finally, multifaceted proposals for improvements in design and performance of TEHVs will be presented as a route map for future research.

show abstract

Section: Heart Implants/prosthesismentioning

confidence: 99%

Collagen–hyaluronic acid based interpenetrating polymer networks as tissue engineered heart valve

Nazir

2016

Materials Science and Technology

View full text Add to dashboard Cite

show abstract

“…In a post-hoc analysis, we compared 2nd ( n = 218) and 3rd generation ( n = 156) CE valves, which are derived from one and two pigs respectively [2]. The prevalence of blood type A according to valve longevity (0–5; 6–14.9; 15–28 years) was 16.7%, 31.6% and 55.6% for the 2nd generation vs. 23.1%, 40.2% and 30.8% for the 3rd generation.…”

Section: Resultsmentioning

confidence: 99%

“…New generations of valves, including most stentless valves and some percutaneous valves, are being made from porcine or bovine tissues. However, to date, none of them is superior to any others and there are no specific clinical guidelines for a particular bioprosthesis [2].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Recipients with blood group A associated with longer survival rates in cardiac valvular bioprostheses

Schussler¹,

Lila

Perneger³

et al. 2019

EBioMedicine

View full text Add to dashboard Cite

Background Pigs/bovines share with humans some of the antigens present on cardiac valves. Two such antigens are: the major xenogenic Ag, “Gal” present in all pig/bovine very close to human B-antigen of ABO-blood-group system; the minor Ag, pig histo-blood-group AH-antigen identical to human AH-antigen and present by some animals. We hypothesize that these antigens may modify the immunogenicity of the bioprosthesis and also its longevity. ABO distribution may vary between patients with low (<6 years) and high (≥15 years) bioprostheses longevity. Methods Single-centre registry study (Paris, France) including all degenerative porcine bioprostheses (mostly Carpentier-Edwards 2nd/3rd generation heart valves) explanted between 1985 and 1998 and some bovine bioprostheses. For period 1998–2014, all porcine bioprostheses with longevity ≥13 years (follow-up ≥29 years). Important predictive factors for bioprosthesis longevity: number, site of implantation, age were collected. Blood group and other variables were entered into an ordinal logistic regression analysis model predicting valve longevity, categorized as low (<6 years), medium (6–14.9 years), and high (≥15 years). Findings Longevity and ABO-blood group were obtained for 483 explanted porcine bioprostheses. Mean longevity was 10.2 ± 3.9 years [0–28] and significantly higher for A-patients than others ( P = 0.009). Using multivariate analysis, group A was a strong predictive factor of longevity (OR 2.09; P < 0.001). For the 64 explanted bovine bioprosthesis with low/medium longevity, the association, with A-group was even more significant. Interpretation Patients of A-group but not B have a higher longevity of their bioprostheses. Future graft-host phenotyping and matching may give rise to a new generation of long-lasting bioprosthesis for implantation in humans, especially for the younger population. Fund None.

show abstract

“…Actualmente, se pueden diferenciar dos tipos: las naturales, que son las válvulas aórticas porcinas [4] y las artificiales, que son válvulas cuyos velos están fabricados a partir de pericardio bovino [5] u otros materiales.…”

Section: Válvulas Biológicasunclassified

Caracterización mecánica de materiales de base colágeno para aplicaciones cardiovasculares

Arnedo¹,

Almudena²

View full text Add to dashboard Cite

Biological replacement heart valves

Cited by 43 publications

References 57 publications

Collagen–hyaluronic acid based interpenetrating polymer networks as tissue engineered heart valve

Collagen–hyaluronic acid based interpenetrating polymer networks as tissue engineered heart valve

Recipients with blood group A associated with longer survival rates in cardiac valvular bioprostheses

Caracterización mecánica de materiales de base colágeno para aplicaciones cardiovasculares

Contact Info

Product

Resources

About